Gossamer Bio (GOSS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Executive summary
Annual meeting scheduled for June 4, 2026, to be held virtually for shareholder participation.
Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report, are available online for review and voting.
Voting matters and shareholder proposals
Shareholders will vote on the election of two Class II directors: Russell Cox and Faheem Hasnain.
Ratification of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026, is on the agenda.
Advisory vote on executive compensation for named executive officers is included.
Board of directors and corporate governance
Board recommends voting in favor of all three proposals presented at the annual meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Gossamer Bio
- Virtual meeting to elect directors, ratify auditor, and approve executive pay, with strong governance.GOSS
Proxy filing24 Apr 2026 - Seralutinib improved 6MWD and biomarkers in high-risk PAH, despite a high placebo response.GOSS
Study result22 Apr 2026 - Seralutinib showed promise in subgroups but missed its primary endpoint, triggering strategic shifts.GOSS
Q4 202517 Mar 2026 - Seralutinib advances in global phase III trials, with Chiesi partnership accelerating PH-ILD expansion.GOSS
Presents at Goldman Sachs 45th Annual Global Healthcare Conference3 Feb 2026 - Seralutinib's phase III trials progress with strong data, global reach, and robust financial backing.GOSS
Guggenheim Securities Inaugural Healthcare Innovation Conference15 Jan 2026 - PROSERA nears enrollment completion, with Q4 data and commercial launch plans progressing.GOSS
Piper Sandler 36th Annual Healthcare Conference12 Jan 2026 - Seralutinib targets late-stage PAH and PH-ILD markets with best-in-class safety and strong commercial prospects.GOSS
Barclays 27th Annual Global Healthcare Conference 202526 Dec 2025 - Seralutinib advances in phase III with best-in-class safety, efficacy, and global reach.GOSS
Leerink’s Global Healthcare Conference 202526 Dec 2025 - Seralutinib’s phase III data in PH, expected late 2024, could reshape the treatment landscape.GOSS
Emerging Growth Conference 7923 Dec 2025